Active Ingredient: semaglutide Inactive Ingredients: disodium phosphate dihydrate, propylene glycol, phenol and water for injection Manufactured by: Novo Nordisk A/S, DK-2880 Bagsvaerd, Denmark OZEMPIC is a registered trademark of Novo Nordisk A/S
This approach can greatly inform further clinical studies and improve patient outcomes. The findings were published in Diabetes, Obesity and Metabolism, with Liang Yiwen, a PhD student from the School of Public Health at HKUMed, as the first author
In clinical protocols it is titrated stepwise (escalation every 4 weeks) to minimise GI side effects
Menstrual changes typically occur during the first three to six months of treatment when weight loss is most rapid
1b, Supplementary Table 26 and Methods)
Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes